BriaCell Advances Phase 3 Trial in Breast Cancer
Company Announcements

BriaCell Advances Phase 3 Trial in Breast Cancer

Story Highlights

BriaCell Therapeutics (TSE:BCT) has released an update.

BriaCell Therapeutics is advancing its pivotal Phase 3 clinical trial for Bria-IMT™ combined with an immune checkpoint inhibitor in metastatic breast cancer, with 35 active sites and enrollment set to complete by mid-2025. This study aims to demonstrate the effectiveness of Bria-IMT™ in improving overall survival compared to traditional treatments, potentially leading to full approval and marketing authorization. The trial has received FDA Fast Track designation, highlighting its potential impact on breast cancer therapy.

For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskBriaCell Shows Promise in Cancer Immunotherapy Advances
TheFlyBriaCell reports preclinical data of personalized off-the-shelf immunotherapies
TipRanks Canadian Auto-Generated NewsdeskBriaCell Unveils Promising Cancer Therapy Data
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App